To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 24 October 2018 to Question 180245 on Prescription Drugs, for what reason his Department did not include individual testimony; and what proportion of the published evidence was submitted by pharmaceutical companies.
‘Prescribed Medicines: An Evidence Review’ is a public health evidence review of the published evidence and available data. This process is distinct from a public inquiry so the inclusion of individual testimonies would not be appropriate.
Public Health England (PHE) is aware of the importance and relevance of the experience of patients in understanding the issues. The review will give significant prominence to the patients’ experiences and examine existing service models through published research and other methods, for example analysis of annual reports of various withdrawal charities.
The call for evidence was open to all parties, including pharmaceutical companies. The call for evidence has now closed. The National Guideline Centre (NGC) will provide details on the evidence submitted in their rapid evidence assessment report. The report is due in early 2019.
A non-disclosure agreement was not made between PHE and the NGC in relation to the review of literature on prescribed medicines.